Herpes zoster events with anifrolumab in patients with active SLE: an integrated analysis of phase 2 and phase 3 trials
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- In the MUSE and TULIP trials, there was an increased risk of herpes zostes (HZ) in patients with systemic lupus erythematosus treated with anifrolumab versus placebo.
- HZ occurred in 5.4%, 6.1%, and 8.6% of patients in the anifrolumab 150 mg, 300 mg, and 1000 mg groups, respectively, and in 1.3% (n=6) of the pooled placebo group.
- HZ event characteristics, including duration and severity, were comparable between treatment groups.
- Most HZ events were mild or moderate, localized cutaneous, and resolved without discontinuation of investigational product.
Presenting Author
Joan Merrill, MD
Oklahoma Medical Research Foundation
Director of Clinical Projects Arthritis & Clinical Immunology Program OMRF
Oklahoma City
Dr. Merrill is the Director of Clinical Projects in the Arthritis & Clinical Immunology Program at the Oklahoma Medical Research Foundation, OMRF Professor of Medicine at the University of Oklahoma Health Sciences Center and the Chief Advisor for Clinical Development for the Lupus Foundation of America. She has decades of experience designing, conducting and interpreting results of clinical trials in SLE, consults for pharmaceutical and biotechnology companies, and recently, in collaboration with colleagues at OMRF, has completed several investigator-initiated studies to test novel approaches to investigate optimal treatment approaches for definable immune phenotypes of SLE patients. She has more than 260 peer-reviewed publications in the field.
Presenter disclosures
J. Merrill, Bristol Myers Squibb, GlaxoSmithKline, AstraZeneca, AbbVie, Amgen, Aurinia, EMD Serono, Remegen, Janssen, Provention, UCB